{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:23:50Z","timestamp":1777922630515,"version":"3.51.4"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.lpm.2021.104070","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T15:08:23Z","timestamp":1632496103000},"page":"104070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metreleptin treatment of non-HIV lipodystrophy syndromes"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6449-3148","authenticated-orcid":false,"given":"Benjamin","family":"Chevalier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3203-717X","authenticated-orcid":false,"given":"Madleen","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-3415","authenticated-orcid":false,"given":"Lysiane","family":"Leguier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristell Le","family":"Mapihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Espiard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lpm.2021.104070_bib0001","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ando.2012.04.010","article-title":"How to diagnose a lipodystrophy syndrome","volume":"73","author":"Vantyghem","year":"2012","journal-title":"Ann d\u2019Endocrinol"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Ara\u00fajo-Vilar","year":"2019","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.lpm.2021.104070_bib0003","first-page":"16","article-title":"Comorbidities and survival in patients with lipodystrophy: an international chart review study","author":"Akinci","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6505","key":"10.1016\/j.lpm.2021.104070_bib0004","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"issue":"5223","key":"10.1016\/j.lpm.2021.104070_bib0005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","article-title":"Weight-reducing effects of the plasma protein encoded by the obese gene","volume":"269","author":"Halaas","year":"1995","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.lpm.2021.104070_bib0006","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1172\/JCI119717","article-title":"Entrainment of the diurnal rhythm of plasma leptin to meal timing","volume":"100","author":"Schoeller","year":"1997","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.lpm.2021.104070_bib0007","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.ijo.0801385","article-title":"Leptin plasma concentrations are dependent on body fat distribution in obese patients","volume":"24","author":"Minocci","year":"2000","journal-title":"Int J Obes"},{"issue":"3","key":"10.1016\/j.lpm.2021.104070_bib0008","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF03339999","article-title":"Are leptin levels dependent on body fat distribution in obese men and women?","volume":"3","author":"Wauters","year":"1998","journal-title":"Eat Weight Disord"},{"issue":"7","key":"10.1016\/j.lpm.2021.104070_bib0009","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2337\/diab.45.7.984","article-title":"Adipose tissue leptin production and plasma leptin kinetics in humans","volume":"45","author":"Klein","year":"1996","journal-title":"Diabetes"},{"issue":"6588","key":"10.1016\/j.lpm.2021.104070_bib0010","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/382250a0","article-title":"Role of leptin in the neuroendocrine response to fasting","volume":"382","author":"Ahima","year":"1996","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.lpm.2021.104070_bib0011","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0092-8674(95)90151-5","article-title":"Identification and expression cloning of a leptin receptor","volume":"83","author":"Tartaglia","year":"1995","journal-title":"OB-R. Cell."},{"issue":"6704","key":"10.1016\/j.lpm.2021.104070_bib0012","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/27376","article-title":"Leptin and the regulation of body weight in mammals","volume":"395","author":"Friedman","year":"1998","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2018-00179","article-title":"Starvation in the Midst of Plenty: Reflections on the History and Biology of Insulin and Leptin","volume":"40","author":"Flier","year":"2019","journal-title":"Endocrine Rev"},{"issue":"2","key":"10.1016\/j.lpm.2021.104070_bib0014","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1073\/pnas.96.2.674","article-title":"Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob\/ob mice","volume":"96","author":"Seufert","year":"1999","journal-title":"Proc Natl Acad Sci"},{"issue":"14","key":"10.1016\/j.lpm.2021.104070_bib0015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137180","article-title":"Leptin decreases de novo lipogenesis in patients with lipodystrophy","volume":"5","author":"Baykal","year":"2020","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.lpm.2021.104070_bib0016","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1172\/JCI200317490","article-title":"The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men","volume":"111","author":"Chan","year":"2003","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0017","doi-asserted-by":"crossref","first-page":"T71","DOI":"10.1530\/JOE-14-0258","article-title":"20 YEARS OF LEPTIN: leptin in common obesity and associated disorders of metabolism","volume":"223","author":"DePaoli","year":"2014","journal-title":"J Endocrinol"},{"issue":"16","key":"10.1016\/j.lpm.2021.104070_bib0018","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.lpm.2021.104070_bib0019","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lpm.2021.104070_bib0020","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/nm1295-1311","article-title":"Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action","volume":"1","author":"Frederich","year":"1995","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.lpm.2021.104070_bib0021","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/db10-1791","article-title":"Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance","volume":"60","author":"Moon","year":"2011","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.lpm.2021.104070_bib0022","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2337\/db14-0625","article-title":"Identification and saturable nature of signaling pathways induced by metreleptin in humans: comparative evaluation of in vivo, ex vivo, and in vitro administration","volume":"64","author":"Moon","year":"2015","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2014.08.004","article-title":"Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism","volume":"64","author":"Park","year":"2015","journal-title":"Metabolism."},{"key":"10.1016\/j.lpm.2021.104070_bib0024","first-page":"dgab216","article-title":"Effect of leptin therapy on survival in generalized and partial lipodystrophy: a matched cohort analysis","author":"Cook","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/19491034.2018.1454167","article-title":"Lipodystrophic laminopathies: diagnostic clues","volume":"9","author":"Guill\u00edn-Amarelle","year":"2018","journal-title":"Nucleus"},{"issue":"6748","key":"10.1016\/j.lpm.2021.104070_bib0026","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.lpm.2021.104070_bib0027","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.lpm.2021.104070_bib0028","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/dom.12606","article-title":"One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes","volume":"18","author":"Vatier","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0029","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12020-014-0450-4","article-title":"Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience","volume":"49","author":"Araujo-Vilar","year":"2015","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.lpm.2021.104070_bib0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1590\/0004-2730000003174","article-title":"Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints","volume":"58","author":"Rodr\u00edguez","year":"2014","journal-title":"Arq Bras Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.lpm.2021.104070_bib0031","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2006-1546","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy","volume":"92","author":"Ebihara","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.lpm.2021.104070_bib0032","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.lpm.2021.104070_bib0033","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.lpm.2021.104070_bib0034","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104070_bib0035","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6156.1000659","article-title":"Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program","author":"Moahad Dar","year":"2016","journal-title":"J Diabetes Metab [Internet]"},{"issue":"4","key":"10.1016\/j.lpm.2021.104070_bib0036","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","article-title":"Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy","volume":"56","author":"Park","year":"2007","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.lpm.2021.104070_bib0037","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","article-title":"Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the dunnigan variety","volume":"97","author":"Simha","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.lpm.2021.104070_bib0038","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1210\/jc.2018-02787","article-title":"Efficacy of metreleptin treatment in familial partial lipodystrophy due to PPARG vs LMNA pathogenic variants","volume":"104","author":"Sekizkardes","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.lpm.2021.104070_bib0039","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.ijo.0801628","article-title":"Long-term leptin treatment of ob\/ob mice improves glucose-induced insulin secretion","volume":"25","author":"Khan","year":"2001","journal-title":"Int J Obes"},{"issue":"8","key":"10.1016\/j.lpm.2021.104070_bib0040","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0041","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/diacare.26.1.30","article-title":"Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy","volume":"26","author":"Simha","year":"2003","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.lpm.2021.104070_bib0042","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.lpm.2021.104070_bib0043","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1210\/jc.2015-3891","article-title":"Effect of leptin administration on circulating apolipoprotein CIII levels in patients with lipodystrophy","volume":"101","author":"Kassai","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.lpm.2021.104070_bib0044","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jacl.2017.02.002","article-title":"Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy","volume":"11","author":"Muniyappa","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.lpm.2021.104070_bib0045","doi-asserted-by":"crossref","first-page":"bvaa191","DOI":"10.1210\/jendso\/bvaa191","article-title":"Apolipoprotein CIII and angiopoietin-like protein 8 are elevated in lipodystrophy and decrease after metreleptin","volume":"5","author":"Lightbourne","year":"2021","journal-title":"J Endocrine Soc"},{"issue":"9","key":"10.1016\/j.lpm.2021.104070_bib0046","doi-asserted-by":"crossref","first-page":"E1676","DOI":"10.1210\/jc.2014-1878","article-title":"Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides","volume":"99","author":"Joseph","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.lpm.2021.104070_bib0047","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ando.2020.07.111","article-title":"Improvement in triglycerides and HDL-cholesterol with metreleptin in lipodystrophic syndromes with mild metabolic syndrome","volume":"81","author":"Leguier","year":"2020","journal-title":"Ann d\u2019Endocrinol"},{"issue":"4","key":"10.1016\/j.lpm.2021.104070_bib0048","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1210\/en.2015-1624","article-title":"Effect of leptin replacement on PCSK9 in ob\/ob mice and female lipodystrophic patients","volume":"157","author":"Levenson","year":"2016","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.lpm.2021.104070_bib0049","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diabet.2016.08.004","article-title":"One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes","volume":"43","author":"Vatier","year":"2017","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1016\/j.lpm.2021.104070_bib0050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/js.2019-00103","article-title":"Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy","volume":"3","author":"Kinzer","year":"2019","journal-title":"J Endocrine Soc"},{"key":"10.1016\/j.lpm.2021.104070_bib0051","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.12688\/f1000research.20150.1","article-title":"Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function","volume":"8","author":"Bruder-Nascimento","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.lpm.2021.104070_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00354","article-title":"Role of leptin in cardiovascular diseases","author":"Poetsch","year":"2020","journal-title":"Front Endocrinol"},{"issue":"S1","key":"10.1016\/j.lpm.2021.104070_bib0053","first-page":"1","article-title":"Metreleptin restores vascular endothelial function in a mouse model of acquired lipodystrophy likely via PPAR\u03b3-dependent reduction in reactive oxygen species","volume":"34","author":"Pearson","year":"2020","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.lpm.2021.104070_bib0054","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.diabet.2018.09.006","article-title":"Cardiometabolic assessment of lamin A\/C gene mutation carriers: a phenotype\u2013genotype correlation","volume":"45","author":"Kwapich","year":"2019","journal-title":"Diabetes Metab"},{"issue":"3","key":"10.1016\/j.lpm.2021.104070_bib0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2015.07.007","article-title":"Leptin does not mediate hypertension associated with human obesity","volume":"162","author":"Brown","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.lpm.2021.104070_bib0056","doi-asserted-by":"crossref","first-page":"bvab019","DOI":"10.1210\/jendso\/bvab019","article-title":"Effects of metreleptin on patient outcomes and quality of life in generalized and partial lipodystrophy","author":"Cook","year":"2021","journal-title":"J Endocrine Soc"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0057","article-title":"The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide","volume":"2020","author":"Akinci","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"10.1016\/j.lpm.2021.104070_bib0058","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1507\/endocrj.EJ19-0226","article-title":"A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles","volume":"67","author":"Fukaishi","year":"2020","journal-title":"Endocr J"},{"issue":"4","key":"10.1016\/j.lpm.2021.104070_bib0059","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.20672","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy","volume":"41","author":"Javor","year":"2005","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.lpm.2021.104070_bib0060","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0061","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.lpm.2021.104070_bib0062","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical Features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.lpm.2021.104070_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199052","article-title":"Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy","volume":"13","author":"Lima","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2021.104070_bib0064","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.metabol.2019.05.001","article-title":"Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and\/or leptin replacement","volume":"96","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/cen.13732","article-title":"Renal complications of lipodystrophy: a closer look at the natural history of kidney disease","volume":"89","author":"Akinci","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.lpm.2021.104070_bib0066","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1210\/jc.2019-00200","article-title":"Effects of metreleptin on proteinuria in patients with lipodystrophy","volume":"104","author":"Lee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.lpm.2021.104070_bib0067","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2003-032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.lpm.2021.104070_bib0068","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.metabol.2011.05.016","article-title":"Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women","volume":"60","author":"Sienkiewicz","year":"2011","journal-title":"Metabolism."},{"issue":"8","key":"10.1016\/j.lpm.2021.104070_bib0069","doi-asserted-by":"crossref","first-page":"E1493","DOI":"10.1210\/jc.2014-1353","article-title":"Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy","volume":"99","author":"Christensen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.lpm.2021.104070_bib0070","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.metabol.2003.10.019","article-title":"Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy","volume":"53","author":"Moran","year":"2004","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.lpm.2021.104070_bib0071","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1210\/jc.2003-031868","article-title":"Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency","volume":"89","author":"McDuffie","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104070_bib0072","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cyto.2018.10.012","article-title":"Beneficial effects of leptin substitution on impaired eating behavior in lipodystrophy are sustained beyond 150\u00a0weeks of treatment","volume":"113","author":"P\u00fcschel","year":"2019","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.lpm.2021.104070_bib0073","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2337\/db15-1550","article-title":"Leptin substitution in patients with lipodystrophy: neural correlates for long-term success in the normalization of eating behavior","volume":"65","author":"Schl\u00f6gl","year":"2016","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0074","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13023-019-1141-2","article-title":"Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes","volume":"14","author":"Vatier","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.lpm.2021.104070_bib0075","unstructured":"Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, Depaoli AM, et\u00a0al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. 8."},{"issue":"2","key":"10.1016\/j.lpm.2021.104070_bib0076","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.metabol.2004.08.021","article-title":"The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients","volume":"54","author":"Musso","year":"2005","journal-title":"Metabolism"},{"issue":"3\u20134","key":"10.1016\/j.lpm.2021.104070_bib0077","first-page":"402","article-title":"Effects of recombinant human leptin (Metreleptin) on nocturnal luteinizing hormone secretion in lipodystrophy patients","volume":"103","author":"Abel","year":"2016","journal-title":"NEN"},{"key":"10.1016\/j.lpm.2021.104070_bib0078","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molimm.2019.05.011","article-title":"An overview of lipodystrophy and the role of the complement system","volume":"112","author":"Corvillo","year":"2019","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0079","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s13256-018-1901-y","article-title":"Acquired partial lipoatrophy as graft-versus-host disease and treatment with metreleptin: two case reports","volume":"12","author":"Shibata","year":"2018","journal-title":"J Med Case Rep"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1210\/jc.2007-1856","article-title":"Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy","volume":"93","author":"Park","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.lpm.2021.104070_bib0081","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1210\/jc.2015-2589","article-title":"A report of three cases with acquired generalized lipodystrophy with distinct autoimmune conditions treated with metreleptin","volume":"100","author":"Lebastchi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.lpm.2021.104070_bib0082","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1210\/jc.2004-1921","article-title":"Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess","volume":"90","author":"Chan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0083","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1038\/s41467-019-13559-7","article-title":"Leptin induces TNF\u03b1-dependent inflammation in acquired generalized lipodystrophy and combined Crohn's disease","volume":"10","author":"Ziegler","year":"2019","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.lpm.2021.104070_bib0084","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104070_bib0085","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/AOG.0b013e31822cecf7","article-title":"Pregnancy in a woman with congenital generalized lipodystrophy: leptin\u2019s vital role in reproduction","volume":"119","author":"Maguire","year":"2012","journal-title":"Obstetr Gynecol"},{"issue":"5","key":"10.1016\/j.lpm.2021.104070_bib0086","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2016-3628","article-title":"Effects of metreleptin in pediatric patients with lipodystrophy","volume":"102","author":"Brown","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.lpm.2021.104070_bib0087","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2016-2271","article-title":"Clinical features and management of non-HIV\u2013related lipodystrophy in children: a systematic review","volume":"102","author":"Gupta","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5\u20136","key":"10.1016\/j.lpm.2021.104070_bib0088","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000341398","article-title":"Consequences of stopping and restarting leptin in an adolescent with lipodystrophy","volume":"78","author":"Kamran","year":"2012","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0089","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/10428194.2015.1040015","article-title":"Lymphoma in acquired generalized lipodystrophy","volume":"57","author":"Brown","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.lpm.2021.104070_bib0090","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1530\/EJE-09-1027","article-title":"Resistance to leptin-replacement therapy in Berardinelli\u2013Seip congenital lipodystrophy: an immunological origin","volume":"162","author":"Beltrand","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0091","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.lpm.2021.104070_bib0092","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13256-016-1175-1","article-title":"Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports","volume":"11","author":"Oliveira","year":"2017","journal-title":"J Med Case Reports"},{"issue":"6","key":"10.1016\/j.lpm.2021.104070_bib0093","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jdi.13309","article-title":"SGLT2 inhibitors for genetic and acquired insulin resistance: considerations for clinical use","volume":"11","author":"Hosokawa","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"12","key":"10.1016\/j.lpm.2021.104070_bib0094","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/dme.13527","article-title":"Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist","volume":"34","author":"Banning","year":"2017","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.lpm.2021.104070_bib0095","doi-asserted-by":"crossref","DOI":"10.15446\/revfacmed.v68n4.77325","article-title":"Uso de metformina y un inhibidor de SGLT2 en el manejo de lipodistrofia cong\u00e9nita generalizada. Reporte de caso","volume":"68","author":"Gonz\u00e1lez-Clavijo","year":"2020","journal-title":"Rev Fac Med"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:36Z","timestamp":1760105316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498221000099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0755498221000099"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104070","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metreleptin treatment of non-HIV lipodystrophy syndromes","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104070"}}